Mursla
Cambridge, Massachusetts, United States
Mursla Bio is a precision medicine and diagnostics company specializing in multi-omics exosome characterization. They develop second-generation liquid biopsy tests using tissue-specific extracellular vesicles (TS-EVs) isolated from blood. Their flagship product, EvoLiver™, detects liver cancer early in high-risk populations. Leveraging an AI Precision Medicine Platform, Mursla combines genomics, proteomics, and machine learning to provide tissue-resolved insights without invasive biopsies. They partner with pharmaceutical companies and healthcare providers to advance biomarker-guided therapies and clinical surveillance.
Company Info
- Founded
- 2017
- Website
- mursla.com/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Mursla?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.